Phase 1 Rare Disease Trial, Recruiting NCT07180355 Sponsor: Solid Biosciences Inc. Condition: Rare Disease
Back to Rare Disease

Phase 1 Rare Disease Trial, Recruiting

NCT07180355
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your first symptoms of Friedreich's Ataxia (FA) started when you were 25 years old or younger
  • You have been diagnosed with FA through both a clinical assessment and genetic testing
  • Your level of disability from FA falls within a specific range on a standard FA rating scale (a score of 1 or higher but less than 6 on the FARS Functional Disability Staging Score)
  • If you are currently taking omaveloxolone (Skyclarys), you have been on the same dose for at least 12 weeks, plan to stay on that dose throughout the study, and are willing to stop taking it if your doctor sees signs of liver problems during the study
  • If you are not currently taking omaveloxolone, at least 12 weeks have passed since your last dose, and you agree not to take it again for 18 months after receiving the study treatment

Who may not be able to join:

  • You have certain antibodies in your blood that react to a virus called AAV9 (used to deliver the gene therapy)
  • Your FA symptom score on a specific assessment (called mFARS) is below 20
  • Your body weight is 25 kg (about 55 lbs) or less, or your body mass index (BMI) is 33 or higher
  • You have a medical reason why you cannot safely have a heart tissue sample taken (endomyocardial biopsy) or a heart catheter procedure
  • You are unable to have an MRI scan of your heart or brain with contrast dye — for example, due to an allergy to the dye used, having a non-MRI-compatible pacemaker or defibrillator, or physical limitations such as joint contractures
  • You have poorly controlled diabetes, shown by a blood sugar marker (HbA1c) above 9%
  • You have taken part in another clinical trial or received an experimental treatment within the past 3 months (or longer, depending on the treatment)
  • You have ever received gene therapy of any kind at any time in the past
  • You have a medical reason why you cannot take steroid medications (corticosteroids)
  • You have a medical reason why you cannot safely undergo the surgical procedure needed to receive the study treatment
  • You have a known heart condition that is not caused by FA, such as blocked heart arteries (coronary artery disease)
  • There may be additional criteria not listed here (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +1617-337-4680

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Solid Biosciences Inc.
Registry
ClinicalTrials.gov
Start date
22 October 2025
Est. completion
21 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov